;PMID: 7554431
;source_file_2890.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..50] = [t:0..50]
;1)sentence:[e:56..165] = [t:56..165]
;2)section:[e:169..220] = [t:169..220]
;3)section:[e:224..294] = [t:224..294]
;4)sentence:[e:298..300] = [t:298..300]
;5)sentence:[e:301..414] = [t:301..414]
;6)sentence:[e:415..540] = [t:415..540]
;7)sentence:[e:541..543] = [t:541..543]
;8)sentence:[e:544..688] = [t:544..688]
;9)sentence:[e:690..821] = [t:690..821]
;10)sentence:[e:822..824] = [t:822..824]
;11)sentence:[e:825..929] = [t:825..929]
;12)sentence:[e:931..933] = [t:931..933]
;13)sentence:[e:934..1007] = [t:934..1007]
;14)sentence:[e:1008..1069] = [t:1008..1069]
;15)sentence:[e:1070..1169] = [t:1070..1169]
;16)sentence:[e:1171..1255] = [t:1171..1255]
;17)sentence:[e:1256..1258] = [t:1256..1258]
;18)sentence:[e:1259..1375] = [t:1259..1375]
;19)section:[e:1379..1423] = [t:1379..1423]

;section 0 Span:0..50
;Clin Exp Pharmacol Physiol.  1995 May;22(5):364-5.
(SEC
  (FRAG (NNP:[0..4] Clin) (NNP:[5..8] Exp) (NNP:[9..18] Pharmacol)
        (NNP:[19..26] Physiol) (.:[26..27] .) (CD:[29..33] 1995)
        (NNP:[34..37] May) (CD:[37..40] ;22) (-LRB-:[40..41] -LRB-)
        (CD:[41..42] 5) (-RRB-:[42..43] -RRB-) (::[43..44] :) (CD:[44..47] 364)
        (CD:[47..49] -5) (.:[49..50] .)))

;sentence 1 Span:56..165
;Subunit-dependent action of lead on neuronal nicotinic acetylcholine
;receptors  expressed in Xenopus oocytes.
;[92..134]:gene-protein:"neuronal nicotinic acetylcholine receptors"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP (NN:[56..63] Subunit) (HYPH:[63..64] -) (JJ:[64..73] dependent))
        (NN:[74..80] action))
      (PP (IN:[81..83] of)
        (NP (NN:[84..88] lead)))
      (PP (IN:[89..91] on)
        (NP (JJ:[92..100] neuronal) (JJ:[101..110] nicotinic)
            (NN:[111..124] acetylcholine) (NNS:[125..134] receptors))))
    (VP (VBN:[136..145] expressed)
      (PP-LOC (IN:[146..148] in)
        (NP (NNP:[149..156] Xenopus) (NNS:[157..164] oocytes))))
    (.:[164..165] .)))

;section 2 Span:169..220
;Oortgiesen M, Zwart R, van Kleef RG, Vijverberg HP.
(SEC
  (FRAG (NNP:[169..179] Oortgiesen) (NNP:[180..182] M,) (NNP:[183..188] Zwart)
        (NNP:[189..190] R) (,:[190..191] ,) (NNP:[192..195] van)
        (NNP:[196..201] Kleef) (NNP:[202..204] RG) (,:[204..205] ,)
        (NNP:[206..216] Vijverberg) (NNP:[217..219] HP) (.:[219..220] .)))

;section 3 Span:224..294
;Research Institute of Toxicology, Utrecht University, The Netherlands.
(SEC
  (FRAG (NNP:[224..232] Research) (NNP:[233..242] Institute) (IN:[243..245] of)
        (NNP:[246..256] Toxicology) (,:[256..257] ,) (NNP:[258..265] Utrecht)
        (NNP:[266..276] University) (,:[276..277] ,) (DT:[278..281] The)
        (NNP:[282..293] Netherlands) (.:[293..294] .)))

;sentence 4 Span:298..300
;1.
(SENT
  (FRAG (LS:[298..300] 1.)))

;sentence 5 Span:301..414
;Pb2+ affects neuronal nicotinic acetylcholine receptors (nAChR) in N1E-115 
;neuroblastoma cells in a dual manner.
;[314..356]:gene-protein:"neuronal nicotinic acetylcholine receptors"
;[358..363]:gene-protein:"nAChR"
;[377..390]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (NN:[301..305] Pb2+))
    (VP (VBZ:[306..313] affects)
      (NP
        (NP (JJ:[314..322] neuronal) (JJ:[323..332] nicotinic)
            (NN:[333..346] acetylcholine) (NNS:[347..356] receptors))
        (NP (-LRB-:[357..358] -LRB-) (NN:[358..363] nAChR)
            (-RRB-:[363..364] -RRB-)))
      (PP-LOC (IN:[365..367] in)
        (NP (NN:[368..375] N1E-115) (NN:[377..390] neuroblastoma)
            (NNS:[391..396] cells)))
      (PP (IN:[397..399] in)
        (NP (DT:[400..401] a) (JJ:[402..406] dual) (NN:[407..413] manner))))
    (.:[413..414] .)))

;sentence 6 Span:415..540
;At nanomolar concentrations a blockade is  observed, while at submillimolar
;concentrations this blocking effect is  reversed.
(SENT
  (S
    (PP (IN:[415..417] At)
      (NP (JJ:[418..427] nanomolar) (NNS:[428..442] concentrations)))
    (NP-SBJ-1 (DT:[443..444] a) (NN:[445..453] blockade))
    (VP (VBZ:[454..456] is)
      (VP (VBN:[458..466] observed)
        (NP-1 (-NONE-:[466..466] *))
        (,:[466..467] ,)
        (SBAR-ADV (IN:[468..473] while)
          (S
            (PP (IN:[474..476] at)
              (NP (JJ:[477..490] submillimolar) (NNS:[491..505] concentrations)))
            (NP-SBJ-2 (DT:[506..510] this) (NN:[511..519] blocking)
                      (NN:[520..526] effect))
            (VP (VBZ:[527..529] is)
              (VP (VBN:[531..539] reversed)
                (NP-2 (-NONE-:[539..539] *))))))))
    (.:[539..540] .)))

;sentence 7 Span:541..543
;2.
(SENT
  (FRAG (LS:[541..543] 2.)))

;sentence 8 Span:544..688
;The Xenopus oocyte expression system was used to examine whether  the dual
;effect of Pb2+ is related to a differential action on nAChR subtypes.
;[673..678]:gene-protein:"nAChR"
(SENT
  (S
    (NP-SBJ-1 (DT:[544..547] The) (NNP:[548..555] Xenopus)
              (NN:[556..562] oocyte) (NN:[563..573] expression)
              (NN:[574..580] system))
    (VP (VBD:[581..584] was)
      (VP (VBN:[585..589] used)
        (NP-1 (-NONE-:[589..589] *))
        (S-ADV
          (NP-SBJ (-NONE-:[589..589] *))
          (VP (TO:[590..592] to)
            (VP (VB:[593..600] examine)
              (SBAR (IN:[601..608] whether)
                (S
                  (NP-SBJ-2
                    (NP (DT:[610..613] the) (JJ:[614..618] dual)
                        (NN:[619..625] effect))
                    (PP (IN:[626..628] of)
                      (NP (NN:[629..633] Pb2+))))
                  (VP (VBZ:[634..636] is)
                    (VP (VBN:[637..644] related)
                      (NP-2 (-NONE-:[644..644] *))
                      (PP-CLR (TO:[645..647] to)
                        (NP
                          (NP (DT:[648..649] a) (JJ:[650..662] differential)
                              (NN:[663..669] action))
                          (PP (IN:[670..672] on)
                            (NP (NN:[673..678] nAChR) (NNS:[679..687] subtypes))))))))))))))
    (.:[687..688] .)))

;sentence 9 Span:690..821
;Effects of Pb2+ were investigated in oocytes expressing nAChR after
;co-injection  of alpha 3 and beta 2 or alpha 3 and beta 4 cDNA.
;[746..751]:gene-protein:"nAChR"
;[775..782]:gene-rna:"alpha 3"
;[787..793]:gene-rna:"beta 2"
;[797..804]:gene-rna:"alpha 3"
;[809..815]:gene-rna:"beta 4"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[690..697] Effects))
      (PP (IN:[698..700] of)
        (NP (NN:[701..705] Pb2+))))
    (VP (VBD:[706..710] were)
      (VP (VBN:[711..723] investigated)
        (NP-1 (-NONE-:[723..723] *))
        (PP (IN:[724..726] in)
          (NP
            (NP (NNS:[727..734] oocytes))
            (VP (VBG:[735..745] expressing)
              (NP (NN:[746..751] nAChR))
              (PP-TMP (IN:[752..757] after)
                (NP
                  (NP (AFX:[758..760] co) (HYPH:[760..761] -)
                      (NN:[761..770] injection))
                  (PP (IN:[772..774] of)
                    (NP
                      (NP
                        (NP
                           (SYM:[775..780] alpha) (CD:[781..782] 3)
                          (NML-2 (-NONE-:[782..782] *P*)))
                        (CC:[783..786] and)
                        (NP
                           (SYM:[787..791] beta) (CD:[792..793] 2)
                          (NML-2 (-NONE-:[793..793] *P*))))
                      (CC:[794..796] or)
                      (NP
                        (NP
                           (SYM:[797..802] alpha) (CD:[803..804] 3)
                          (NML-2 (-NONE-:[804..804] *P*)))
                        (CC:[805..808] and)
                        (NP
                           (SYM:[809..813] beta) (CD:[814..815] 4)
                          (NML-2 (NN:[816..820] cDNA)))))))))))))
    (.:[820..821] .)))

;sentence 10 Span:822..824
;3.
(SENT
  (FRAG (LS:[822..824] 3.)))

;sentence 11 Span:825..929
;At 1-250 mumol/L, Pb2+  causes a 10-1000% increase of the response mediated
;by the alpha 3 beta 2 nAChR.
;[908..928]:gene-protein:"alpha 3 beta 2 nAChR"
(SENT
  (S
    (PP (IN:[825..827] At)
      (NP
        (NP (CD:[828..829] 1) (HYPH:[829..830] -) (CD:[830..833] 250)
            (NN:[834..839] mumol))
        (PP (SYM:[839..840] /)
          (NP (NN:[840..841] L)))))
    (,:[841..842] ,)
    (NP-SBJ (NN:[843..847] Pb2+))
    (VP (VBZ:[849..855] causes)
      (NP
        (NP (DT:[856..857] a)
          (NML
            (QP (CD:[858..860] 10) (HYPH:[860..861] -) (CD:[861..865] 1000))
            (NN:[865..866] %))
          (NN:[867..875] increase))
        (PP (IN:[876..878] of)
          (NP
            (NP (DT:[879..882] the) (NN:[883..891] response))
            (VP (VBN:[892..900] mediated)
              (NP (-NONE-:[900..900] *))
              (PP (IN:[901..903] by)
                (NP-LGS (DT:[904..907] the)
                   (SYM:[908..913] alpha) (CD:[914..915] 3)
                   (SYM:[916..920] beta) (CD:[921..922] 2) (NN:[923..928] nAChR))))))))
    (.:[928..929] .)))

;sentence 12 Span:931..933
;4.
(SENT
  (FRAG (LS:[931..933] 4.)))

;sentence 13 Span:934..1007
;Pb2+ blocks ACh-induced inward currents mediated by alpha 3 beta 4 nAChR.
;[986..1007]:gene-protein:"alpha 3 beta 4 nAChR."
(SENT
  (S
    (NP-SBJ (NN:[934..938] Pb2+))
    (VP (VBZ:[939..945] blocks)
      (NP
        (NP
          (ADJP (NN:[946..949] ACh) (HYPH:[949..950] -) (VBN:[950..957] induced))
          (JJ:[958..964] inward) (NNS:[965..973] currents))
        (VP (VBN:[974..982] mediated)
          (NP (-NONE-:[982..982] *))
          (PP (IN:[983..985] by)
            (NP-LGS (SYM:[986..991] alpha) (CD:[992..993] 3)
                    (SYM:[994..998] beta) (CD:[999..1000] 4)
                    (NN:[1001..1006] nAChR))))))
    (.:[1006..1007] .)))

;sentence 14 Span:1008..1069
;The  inhibitory potency of Pb2+ greatly varies between cells.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1008..1011] The) (JJ:[1013..1023] inhibitory)
          (NN:[1024..1031] potency))
      (PP (IN:[1032..1034] of)
        (NP (NN:[1035..1039] Pb2+))))
    (ADVP (RB:[1040..1047] greatly))
    (VP (VBZ:[1048..1054] varies)
      (PP (IN:[1055..1062] between)
        (NP (NNS:[1063..1068] cells))))
    (.:[1068..1069] .)))

;sentence 15 Span:1070..1169
;In 50% of the cells  concentrations < or = 1 mumol/L Pb2+ blocked the
;nicotinic response by 31-93%.
(SENT
  (S
    (PP (IN:[1070..1072] In)
      (NP
        (NP (CD:[1073..1075] 50) (NN:[1075..1076] %))
        (PP (IN:[1077..1079] of)
          (NP (DT:[1080..1083] the) (NNS:[1084..1089] cells)))))
    (NP-SBJ
      (NP
        (NP (NNS:[1091..1105] concentrations))
        (VP (SYM:[1106..1107] <) (CC:[1108..1110] or) (SYM:[1111..1112] =)
          (NP
            (NP (CD:[1113..1114] 1) (NN:[1115..1120] mumol))
            (PP (SYM:[1120..1121] /)
              (NP (NN:[1121..1122] L))))))
      (NP-SBJ (NN:[1123..1127] Pb2+)))
    (VP (VBD:[1128..1135] blocked)
      (NP (DT:[1136..1139] the) (JJ:[1140..1149] nicotinic)
          (NN:[1150..1158] response))
      (PP-EXT (IN:[1159..1161] by)
        (NP
          (QP (CD:[1162..1164] 31) (HYPH:[1164..1165] -) (CD:[1165..1167] 93))
          (NN:[1167..1168] %))))
    (.:[1168..1169] .)))

;sentence 16 Span:1171..1255
;In the other cells even at higher concentrations Pb2+ caused only 0-65% 
;inhibition.
(SENT
  (S
    (PP-LOC (IN:[1171..1173] In)
      (NP (DT:[1174..1177] the) (JJ:[1178..1183] other) (NNS:[1184..1189] cells)))
    (PP
      (ADVP (RB:[1190..1194] even))
      (IN:[1195..1197] at)
      (NP (JJR:[1198..1204] higher) (NNS:[1205..1219] concentrations)))
    (NP-SBJ (NN:[1220..1224] Pb2+))
    (VP (VBD:[1225..1231] caused)
      (NP
        (NML
          (QP (RB:[1232..1236] only) (CD:[1237..1238] 0) (HYPH:[1238..1239] -)
              (CD:[1239..1241] 65))
          (NN:[1241..1242] %))
        (NN:[1244..1254] inhibition)))
    (.:[1254..1255] .)))

;sentence 17 Span:1256..1258
;5.
(SENT
  (FRAG (LS:[1256..1258] 5.)))

;sentence 18 Span:1259..1375
;These results show that Pb2+ may both potentiate and block nAChR,  depending
;on the type of nAChR subunit expressed.
;[1318..1323]:gene-protein:"nAChR"
;[1351..1356]:gene-protein:"nAChR"
(SENT
  (S
    (NP-SBJ (DT:[1259..1264] These) (NNS:[1265..1272] results))
    (VP (VBP:[1273..1277] show)
      (SBAR (IN:[1278..1282] that)
        (S
          (NP-SBJ (NN:[1283..1287] Pb2+))
          (VP (MD:[1288..1291] may)
            (VP (CC:[1292..1296] both) (VB:[1297..1307] potentiate)
                (CC:[1308..1311] and) (VB:[1312..1317] block)
              (NP (NN:[1318..1323] nAChR))
              (,:[1323..1324] ,)
              (PP (VBG:[1326..1335] depending)
                (PP (IN:[1336..1338] on)
                  (NP
                    (NP (DT:[1339..1342] the) (NN:[1343..1347] type))
                    (PP (IN:[1348..1350] of)
                      (NP
                        (NP (NN:[1351..1356] nAChR) (NN:[1357..1364] subunit))
                        (VP (VBN:[1365..1374] expressed)
                          (NP (-NONE-:[1374..1374] *)))))))))))))
    (.:[1374..1375] .)))

;section 19 Span:1379..1423
;PMID: 7554431 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1379..1383] PMID) (::[1383..1384] :) (CD:[1385..1392] 7554431)
        (NN:[1393..1394] -LSB-) (NNP:[1394..1400] PubMed) (::[1401..1402] -)
        (NN:[1403..1410] indexed) (IN:[1411..1414] for)
        (NNP:[1415..1423] MEDLINE-RSB-)))
